Prof Mariana Brandão, medical oncologist at Institute Jules Bordet, Hôpital Universitaire de Bruxelles presents a phase I/IIa study that aims to investigate the efficacy and safety of dry powder inhaled cisplatin in stage IV NSCLC patients. With the educational support of: You may also be interested in: Immunotherapy in the peri-operative treatment of patients with early-stage NSCLC The phase I/IIa CIS-DPI-01 study A propensity-based analysis of SBRT & VATS for early-stage lung cancer Tags:poster